The S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNeP) caused a reduction in EZH2, resulting in a genome-wide decrease in H3K27 methylation and apoptosis in a variety of different cancers including breast cancer, colorectal cancer, and prostate cancer, while DZNeP left normal cells unaffected; conversely, DZNeP also decreased the methylation of many other histone residues [171,172,173]. This evidence concerns the gene EZH2 and cancer.